Lenalidomide: In vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 6, 2009, Pages 1171-1175

  Kumar, Gondi ^a   Lau, Henry ^a   Laskin, Oscar ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

CYP induction; CYP inhibition; Cytochrome P450; Drug drug interactions; Lenalidomide

Indexed keywords

CYTOCHROME P450; DISULFIRAM; LENALIDOMIDE; LIVER ENZYME; MICONAZOLE; OMEPRAZOLE; PHENOBARBITAL; QUINIDINE; RIFAMPICIN; SULFAPHENAZOLE; TRANYLCYPROMINE;

ARTICLE; CELL CULTURE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HUMANS; ISOENZYMES; MICROSOMES, LIVER; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; THALIDOMIDE;

EID: 63949087792     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0867-7     Document Type: Article

References (18)

1. PH Schafer AK Gandhi MA Loveland 2003 Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs J Pharmacol Exp Ther 305 3 1222 1232
2. AK Gandhi J Kang S Naziruddin 2006 Lenalidomide inhibits proliferation of Namalwa CSN. 70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly Leuk Res 30 7 849 858
3. A List S Kurtin DJ Roe 2005 Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 6 549 557
4. M Melchert V Kale A List 2007 The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes Curr Opin Hematol 14 2 123 129
5. PG Richardson E Blood CS Mitsiades 2006 A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma Blood 108 10 3458 3464
6. SV Rajkumar SR Hayman MQ Lacy 2005 Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Blood 106 13 4050 4053
7. S Thomas R Alexanian 2007 Current treatment strategies for multiple myeloma Clin Lymphoma Myeloma 7 suppl 4 S139 S144
8. S Molica 2007 Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm Leuk Lymphoma 48 5 866 869
9. R Dreicer 2007 Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors Curr Oncol Rep 9 2 120 123
10. AA Chanan-Khan BD Cheson 2008 Lenalidomide for the treatment of B-cell malignancies J Clin Oncol 26 9 1544 1552
11. DJ Back ML Orme 1990 Pharmacokinetic drug interactions with oral contraceptives Clin Pharmacokinet 18 6 472 484
12. BK Park NR Kitteringham M Pirmohamed 1996 Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications Br J Clin Pharmacol 41 6 477 491
13. DM Gentile ES Tomlinson JL Maggs 1996 Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation J Pharmacol Exp Ther 277 1 105 112
14. JM Pascussi L Drocourt JM Fabre 2000 Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators Mol Pharmacol 58 2 361 372
15. E LeCluyse A Madan G Hamilton 2000 Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes J Biochem Mol Toxicol 14 4 177 188
16. A Madan RA Graham KM Carroll 2003 Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes Drug Metab Dispos 31 4 421 431
17. Quistorff B, Dich J, Grunnet N (1989) Preparation of isolated rat liver hepatocytes. In: Pollard JW, Walker JM (eds) Methods in molecular biology, vol 5. Animal cell culture. Humana Press, New Jersey, pp 151-160
18. N Chen H Lau L Kong 2007 Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis J Clin Pharmacol 47 12 1466 1475